5:06 PM
 | 
Sep 27, 2018
 |  BC Innovations  |  Emerging Company Profile

GDF11 against aging

How Elevian is tackling age-related diseases with GDF11

Harvard University spinout Elevian Inc. is developing a regenerative platform around GDF11 to treat age-related diseases, including Alzheimer's disease. The company, which emerged from stealth on Sept. 6, aims to modulate the protein’s pathway with antibodies, small molecules, or recombinant versions of the protein itself.

GDF11, part of the transforming growth factor β (TGFβ) family, affects cellular growth and development; and GDF deficiency in mice causes developmental abnormalities, such as agenesis of the kidneys and perinatal lethality.

CEO Mark Allen said Elevian has exclusive, worldwide rights to more than a dozen pending patents from Harvard and its research partners covering modulation of GDF11 and related ligands. The Harvard researchers -- Elevian scientific co-founders Lee Rubin, Rich Lee, Amy Wagers and Ryan Walker -- have been publishing findings on GDF11 since 2005.

In a...

Read the full 655 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >